Dean Fennell

Dean Fennell at the University of Leicester is a leading UK mesothelioma researcher who contributed to the CONFIRM trial demonstrating nivolumab efficacy in previously treated mesothelioma and has been central to UK mesothelioma clinical research. His laboratory has characterized the molecular biology of BAP1 loss and other genomic features of mesothelioma, contributing to therapeutic target identification. He has been a strong advocate for the MARS2 surgical trial addressing ongoing controversies about radical resection. His work on molecularly targeted approaches to mesothelioma has advanced the field beyond standard chemotherapy.